Gossamer Bio (NASDAQ:GOSS) Receives Overweight Rating from Cantor Fitzgerald

Key Points

• Gossamer Bio's stock maintains an "overweight" rating from Cantor Fitzgerald, while other analysts show mixed sentiments with ratings ranging from "buy" to "sell".
• The company's stock price has increased by 12.3%, with a current market capitalization of approximately $707.15 million.
• Gossamer Bio reported a quarterly earnings of ($0.17) EPS, beating estimates, and generated significant revenue of $11.49 million compared to the expected $4.12 million.

Cantor Fitzgerald reiterated their overweight rating on shares of Gossamer Bio (NASDAQ:GOSS - Free Report) in a research note issued to investors on Thursday morning,Benzinga reports.

A number of other research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. The Goldman Sachs Group increased their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, May 16th. Wedbush raised their price target on shares of Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a research report on Wednesday, August 6th. Finally, Scotiabank started coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They set a "sector outperform" rating and a $11.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $8.50.

Gossamer Bio Trading Up 0.8%

Shares of Gossamer Bio stock traded up $0.03 on Thursday, hitting $3.21. 2,107,043 shares of the company traded hands, compared to its average volume of 2,224,515. The stock's 50 day moving average price is $2.12 and its 200-day moving average price is $1.48. The company has a market cap of $728.76 million, a PE ratio of -5.17 and a beta of 1.95. The company has a current ratio of 4.40, a quick ratio of 4.40 and a debt-to-equity ratio of 6.70. Gossamer Bio has a 52 week low of $0.66 and a 52 week high of $3.60.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%.The firm had revenue of $11.49 million for the quarter, compared to the consensus estimate of $4.12 million. Equities research analysts predict that Gossamer Bio will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Gossamer Bio

A number of institutional investors have recently modified their holdings of GOSS. Legal & General Group Plc acquired a new position in Gossamer Bio during the second quarter worth approximately $26,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio during the second quarter worth approximately $27,000. Drive Wealth Management LLC increased its position in Gossamer Bio by 52.7% during the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company's stock worth $31,000 after purchasing an additional 8,797 shares during the last quarter. Graham Capital Management L.P. acquired a new position in Gossamer Bio during the fourth quarter worth approximately $32,000. Finally, Virtu Financial LLC acquired a new position in Gossamer Bio during the first quarter worth approximately $38,000. Institutional investors and hedge funds own 81.23% of the company's stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.